Equities

All Cosmos Bio-Tech Holding Corp

4148:TAI

All Cosmos Bio-Tech Holding Corp

Actions
Basic MaterialsChemicals
  • Price (TWD)55.30
  • Today's Change1.80 / 3.36%
  • Shares traded210.33k
  • 1 Year change+38.77%
  • Beta--
Data delayed at least 20 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in TWD

The one analyst offering a 12 month price target expects All Cosmos Bio-Tech Holding Corp share price to rise to 97.00 in the next year from the last price of 55.30.
High75.4%97.00
Med75.4%97.00
Low75.4%97.00

Earnings history & estimates in TWD

On Nov 12, 2024, All Cosmos Bio-Tech Holding Corp reported 3rd quarter 2024 earnings of 1.11 per share. This result exceeded the 0.51 expectation of the one analyst covering the company and exceeded last year's 3rd quarter results by 3.74%.
The next earnings announcement is expected on Mar 20, 2025.
Average growth rate+380.15%
All Cosmos Bio-Tech Holding Corp reported annual 2023 earnings of 2.13 per share on Mar 14, 2024.
Average growth rate+72.63%
More ▼

Revenue history & estimates in TWD

All Cosmos Bio-Tech Holding Corporation had 3rd quarter 2024 revenues of 746.29m. This bettered the 578.00m estimate of the one analyst covering the company. This was 4.07% below the prior year's 3rd quarter results.
Average growth rate+5.49%
All Cosmos Bio-Tech Holding Corporation had revenues for the full year 2023 of 2.83bn. This was 23.65% below the prior year's results.
Average growth rate+17.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.